Destination XL Group (DXLG) Q2 2027 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2027 earnings summary
9 Sep, 2026Executive summary
Q2 sales were $111.6 million, down 3.4% year-over-year, with comparable sales declining 3.5%.
Net income was $2.0 million ($0.04 per diluted share), compared to a net loss of $0.3 million last year; adjusted EPS was $0.05, up from $0.01.
Gross margin improved to 47.9% from 45.2%, aided by a $4.6 million IEEPA tariff refund.
Adjusted EBITDA rose to $7.7 million (6.9% of sales), up from $4.7 million last year.
The board withdrew support for the FullBeauty merger due to FullBeauty's deteriorating financials and increased risk.
Financial highlights
Net sales: $111.6 million, down from $115.5 million year-over-year.
Adjusted EBITDA: $7.7 million (6.9% margin); six-month adjusted EBITDA: $6.9 million (3.2% margin).
Adjusted EPS: $0.05, up from $0.01 last year.
Gross margin (including occupancy): 47.9%, up 270 bps, aided by a $4.6 million tariff refund.
Cash and investments: $20.1 million at quarter end, no debt, and $61.7 million in credit facility availability.
Outlook and guidance
Management expects continued performance improvements, focusing on disciplined operations and execution.
Marketing costs for fiscal 2026 expected to be 5.8% of sales.
Capital expenditures for fiscal 2026 projected at $8–10 million, focused on technology and store maintenance.
Store rationalization will have limited impact in 2026 but is expected to reduce costs from 2027 onward.
Cash and credit facility expected to cover liquidity and capital needs for at least 12 months.
Latest events from Destination XL Group
- Board recommends voting against the merger due to FBB’s financial decline and increased risk.DXLG
Proxy filing - Board now recommends voting against the FullBeauty merger issuance proposal due to risk concerns.DXLG
Proxy filing - Board recommends voting against the FullBeauty merger due to debt and dilution concerns.DXLG
Proxy filing - DXL's Board reverses support for merger, citing dilution and risk, and urges a vote against share issuance.DXLG
Proxy filing - Sales fell 2.1% and net loss widened amid macro pressures, merger costs, and strong liquidity.DXLG
Q1 2027 - Sales and margins declined in 2025, with a major merger expected to close in Q2 2026.DXLG
Q4 2026 - Sales declined and a merger with FullBeauty aims for $25M synergies and $1.2B sales.DXLG
Q3 2026 - Sales and margins declined, but inventory and liquidity remained strong.DXLG
Q3 2025 - Q2 sales and profit dropped, leading to lower full-year guidance and tighter capital discipline.DXLG
Q2 2025